G1 Therapeutics Probability of Future Stock Price Finishing Under 3.03
| GTHXDelisted Stock | USD 7.15 0.00 0.00% |
GTHX |
G1 Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of G1 Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for G1 Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| G1 Therapeutics is not yet fully synchronised with the market data | |
| G1 Therapeutics generated a negative expected return over the last 90 days | |
| G1 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M. | |
| G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
G1 Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GTHX Stock often depends not only on the future outlook of the current and potential G1 Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. G1 Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 51.7 M | |
| Cash And Short Term Investments | 82.2 M |
G1 Therapeutics Technical Analysis
G1 Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. GTHX Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of G1 Therapeutics. In general, you should focus on analyzing GTHX Stock price patterns and their correlations with different microeconomic environments and drivers.
G1 Therapeutics Predictive Forecast Models
G1 Therapeutics' time-series forecasting models is one of many G1 Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary G1 Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about G1 Therapeutics
Checking the ongoing alerts about G1 Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for G1 Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| G1 Therapeutics is not yet fully synchronised with the market data | |
| G1 Therapeutics generated a negative expected return over the last 90 days | |
| G1 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.51 M. Net Loss for the year was (47.97 M) with profit before overhead, payroll, taxes, and interest of 47.55 M. | |
| G1 Therapeutics currently holds about 143.96 M in cash with (38.34 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.37. |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Other Consideration for investing in GTHX Stock
If you are still planning to invest in G1 Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the G1 Therapeutics' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| CEOs Directory Screen CEOs from public companies around the world |